Huntington's Disease (HD)
Patient Condition
Early Huntington's disease, CAG repetition number 42, mild chore-like movement, normal cognitive function, MoCA score 27. UHDRS TMS 12 points, TFC 13 points. Selected into the clinical trial of intranasal administration of neural stem cells.
Treatment Timeline
| Phase | Details | Date |
|---|---|---|
| Clinical trial screening and baseline assessment | ||
| Intranasal administration of neural stem cells | ||
| Session 2 + Rehabilitation Training | ||
| Follow-up assessment and maintenance rehabilitation |
Treatment Outcome
| before | UHDRS TMS 12, TFC 13, MoCA 27, mild choreo-like movements, normal cognitive function |
|---|---|
| after | UHDRS TMS dropped to 6 points (improved by 6 points), TFC maintained at 13 points, MoCA maintained at 27 points, and choreo-like movements almost disappeared |
| highlight | The non-invasive intranasal administration of neural stem cells is safe, motor symptoms are significantly improved, and the non-invasive administration method is highly accepted by patients. |